Photo-oxidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-14. Numbers and descriptions here follow the published literature rather than marketing material.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
In May 2018, the United States imposed sanctions on Iran's IRGC, which was also listed as a designated terrorist organization by the US over its role in providing support for the Houthis, including help with manufacturing ballistic missiles used in attacks targeting cities and oil fields in Saudi Arabia. In August 2018, despite previous Iranian denial of military support for the Houthis, IRGC commander Nasser Shabani was quoted by the Iranian Fars News Agency as saying, "We (IRGC) told Yemenis [Houthi rebels] to strike two Saudi oil tankers, and they did it", on 7 August 2018. In response to Shabani's account, the IRGC released a statement saying that the quote was a "Western lie" and that Shabani was a retired commander, despite no actual reports of his retirement after 37 years in the IRGC, and media linked to the Iranian government confirming he was still enlisted with the IRGC. Furthermore, while the Houthis and the Iranian government have previously denied any military affiliation, Iranian supreme leader Ali Khamenei announced his "spiritual" support of the movement in a personal meeting with the Houthi spokesperson Mohammed Abdul Salam in Tehran, in the midst of ongoing conflicts in Aden in 2019. In 2024, commanders from IRGC and Hezbollah were reported to be actively involved on the ground in Yemen, overseeing and directing Houthi attacks on Red Sea shipping, according to a report by Reuters. In July 2024, the United States targeted new sanctions focusing on IRGC ties with the group. The Houthis dismissed the sanctions as pathetic and powerless.
In April 2021 Noakes pleaded guilty in France to manufacturing and selling fake medicinal products and cosmetics by Internet and sentenced to 4 years of jail. A 2019 Business Insider report detailed the activities of Amanda Mary Jewell, who sold GcMAF for years as an unlicensed cure for several medical conditions, including cancer and autism. Jewell is not a medical doctor.
His researches made from 1899 to 1906 were published in 1907 with the title Untersuchungen über Aminosauren, Polypeptides und Proteine. Three years later the total number of peptides exceeded 100, with the longest being an 18 amino acid peptide containing 15 glycine and three leucine units. The 18 amino acid peptide gave the standard responses to tests for proteins used by physiological chemists - a positive Biuret test, precipitation by inorganic salts and cleavage by proteolytic enzymes
Limited/selective fasciectomy removes the pathological tissue, and is a common approach. A 2015 Cochrane review reported that low-quality evidence suggested that fasciectomy may be more effective for people with advanced Dupuytren's contractures. During the procedure, the person is under regional or general anesthesia. A surgical tourniquet prevents blood flow to the limb. The skin is often opened with a zig-zag incision but straight incisions with or without Z-plasty are also described and may reduce damage to neurovascular bundles. All diseased cords and fascia are excised. The excision has to be very precise to spare the neurovascular bundles. Because not all the diseased tissue is visible macroscopically, complete excision is uncertain. A 20-year review of surgical complications associated with fasciectomy showed that major complications occurred in 15.7% of cases, including digital nerve injury (3.4%), digital artery injury (2%), infection (2.4%), hematoma (2.1%), and complex regional pain syndrome (5.5%), in addition to minor complications including painful flare reactions in 9.9% of cases and wound healing complications in 22.9% of cases. After the tissue is removed the incision is closed. In the case of a shortage of skin, the transverse part of the zig-zag incision is left open. Stitches are removed 10 days after surgery. After surgery, the hand is wrapped in a light compressive bandage for one week. Flexion and extension of the fingers can start as soon as the anaesthesia has resolved. It is common to experience tingling within the first week after surgery.
Sources: en.wikipedia.org
=== Availability/affordability === Infliximab is supplied as a sterile, white, lyophilized (freeze-dried) powder, so must be reconstituted and administered by a health care professional, usually in a hospital or office setting. For this reason, it is usually covered under major medical insurance rather than prescription drug coverage. The loading regimen for all approved indications occurs at weeks 0, 2, and 6 at the above dosages. In the UK, infliximab is available from the NHS for Crohn's disease treatment provided three criteria are met. Patients should have severe active Crohn's disease with a CDAI score of 300 or more, have not responded to immunomodulating drugs and corticosteroids, and for whom surgery is inappropriate. Since February 2015, it is also approved for the treatment of ulcerative colitis where other treatments have not worked. In Australia, infliximab is available through the PBS for Crohn's disease treatment provided the patient has not responded to conventional treatment and has a severe case of the condition. Johnson & Johnson reported in its 2013 annual report, "Remicade (infliximab), accounted for approximately 9.4% of the Company's total revenues for fiscal 2013." A self-injectable, subcutaneous version of infliximab, Zymfentra, was approved for medical use in the United States in October 2023.
28 October 2014: Wilkinson A/L Primus, a Malaysian convicted of trafficking heroin in 2008 and sentenced to death in 2009. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced to life imprisonment in 2014 on the grounds that he was intellectually challenged and suffering from depression at the time of the crime. 20 April 2015: Cheong Chun Yin, a Malaysian convicted of trafficking heroin in 2008 and sentenced to death in 2010. He lost his appeal to the Court of Appeal in 2010. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2015 to life imprisonment and 15 strokes of the cane. His boss and accomplice, Pang Siew Fum, was also re-sentenced to life imprisonment on the same day, due to Pang suffering from depression at the time of the crime. 1 July 2015: Kester Ng Wei Ren, a 47-year-old Singaporean caught trafficking in 23.38g of heroin on 12 August 2008. He tried to argue that he only meant to import only 9.92g of heroin while the rest of his drug supply was only meant for his own consumption. Ng was given the mandatory death penalty in 2010 and he also lost his appeal in the same year. After changes to the law took effect in 2013, Ng applied for re-sentencing but he did not meet the criteria to be re-sentenced to life imprisonment. Hence he lost his appeal to be re-sentenced on 1 July 2015 since he was not certified as a courier. He was presumably executed sometime following the loss of his re-sentencing application.
=== The Healing Foundation === In 1998, as Treasurer of the British Association of Plastic, Reconstructive, and Aesthetic Surgeons (BAPRAS), Brough and his fellow Trustees established The Healing Foundation. Building on the groundwork laid by the Phoenix Appeal, The Healing Foundation aimed to advance research into surgical and psychological healing techniques for individuals with disfiguring conditions. Various UK medical membership bodies provided support to The Healing Foundation as Partner Member Organisations. These partnerships bolstered the charity's credibility, networking capabilities, and financial resources.These organisations were BAPRAS, the British Association of Aesthetic Surgeons, the British Psychological Society, the Craniofacial Society of Great Britain and Ireland, the British Burns Association, and the British Society for Surgery of the Hand.
Sources: en.wikipedia.org
The origins of the concept of hotspots lie in the work of J. Tuzo Wilson, who postulated in 1963 that the formation of the Hawaiian Islands resulted from the slow movement of a tectonic plate across a hot region beneath the surface. It was later postulated that hotspots are fed by streams of hot mantle rising from the Earth's core–mantle boundary in a structure called a mantle plume. Whether or not such mantle plumes exist has been the subject of a major controversy in Earth science, but seismic images consistent with evolving theory now exist. At any place where volcanism is not linked to a constructive or destructive plate margin, the concept of a hotspot has been used to explain its origin. A review article by Courtillot et al. listing possible hotspots makes a distinction between primary hotspots coming from deep within the mantle and secondary hotspots derived from mantle plumes. The primary hotspots originate from the core/mantle boundary and create large volcanic provinces with linear tracks (Easter Island, Iceland, Hawaii, Afar, Louisville, Reunion, and Tristan confirmed; Galapagos, Kerguelen and Marquersas likely). The secondary hotspots originate at the upper/lower mantle boundary, and do not form large volcanic provinces, but island chains (Samoa, Tahiti, Cook, Pitcairn, Caroline, MacDonald confirmed, with up to 20 or so more possible). Other potential hotspots are the result of shallow mantle material surfacing in areas of lithospheric break-up caused by tension and are thus a very different type of volcanism.
Official governmental portal Archived 17 April 2024 at the Wayback Machine Official website for tourism and holiday in Lower Saxony Archived 5 May 2018 at the Wayback Machine Map with tourist highlights, notepad and personal guide Archived 26 March 2009 at the Wayback Machine (in German) Geographic data related to Lower Saxony at OpenStreetMap
For decades, the public viewed the house as the "Birthplace of Insulin," and many individuals expressed their desire to have it turned into a shrine or monument to honour the Canadian hero. It was first internationally referred to with the title "Birthplace of Insulin," in 1923, by the Detroit Free Press. After 47 years, the house received official recognition in 1970, in the form of a plaque for the house, awarded by the London Public Library Board. In 1981, the London & District Branch of the Canadian Diabetes Association purchased the house, and began to use it as an office; they hoped to eventually restore the house, and turn it into a museum. Through various grants and fundraising efforts, by 1984, the museum was operational.
Neptunium at The Periodic Table of Videos (University of Nottingham) Lab builds world's first neptunium sphere Archived 2006-09-25 at the Wayback Machine, U.S. Department of Energy Research News NLM Hazardous Substances Databank – Neptunium, Radioactive Neptunium: Human Health Fact Sheet Archived 2004-02-06 at the Wayback Machine C&EN: It's Elemental: The Periodic Table – Neptunium
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.